Biolinerx Ltd. (BLRX)

Trade BLRX now with
1/17/2018 7:02:34 AM BioLineRx Announces Partial Monotherapy Results From Phase 2a COMBAT Study In Pancreatic Cancer
12/21/2017 7:03:15 AM BioLineRx Begins Phase 3 GENESIS Clinical Trial
12/4/2017 7:03:20 AM BioLineRx Reports Overall Survival Results From Long-term Follow-up Of Phase 2a Trial In R/r AML
11/21/2017 7:05:33 AM BioLineRx Q3 Loss Per Share $0.08 Vs Loss $0.07 Last Year
11/20/2017 7:07:52 AM BioLineRx Says Partial Results Of BL-8040 COMBAT Study Accepted For Presentation At ASCO 2018
10/18/2017 7:05:08 AM BioLineRx: Genentech Begin Phase 1b/2 Study For Treatment Of Gastric Cancer With BL-8040 Plus Atezolizumab
9/26/2017 7:05:31 AM BioLineRx Says Begins Phase 1b/2 Trial For BL-8040 In AML Under Immunotherapy Collaboration
8/21/2017 7:04:55 AM BioLineRx Announces Regulatory Submission Of Phase 3 Registrational Study For BL-8040 In Stem Cell Mobilization
8/8/2017 7:11:04 AM BioLineRx Ltd. Q2 Net Loss Widens To $4.9 Mln From $3.7 Mln Last Year
7/10/2017 7:02:58 AM BioLineRx Begins Phase 1b/2 Trial Of BL-8040 In Pancreatic Cancer Under Immunotherapy Collaboration
5/25/2017 7:11:43 AM BioLineRx Q1 Net Loss $4.9 Mln Vs Loss Of $3.5 Mln Last Year
5/22/2017 7:02:14 AM BioLineRx Announces Regulatory Submission For Phase 1b Trial Of BL-8040 In Combination With Atezolizumab In AML
3/31/2017 8:28:07 AM BioLineRx Prices Underwritten Public Offering Of About 29.4 Mln ADSs At $0.85 Per ADS For Gross Proceeds Of $25 Mln
3/23/2017 8:04:52 AM BioLineRx 2016 Net Loss $15.8 Mln Vs. Net Loss Of $14.4 Mln Prior Year
12/5/2016 7:24:28 AM BioLineRx Presents Positive Phase 2a AML Study And Mechanism-of-Action Data For BL-8040 Oncology Platform
11/21/2016 7:06:57 AM BioLineRx In-licenses Novel Anti-Inflammatory Treatment For Dry Eye Syndrome Under Collaboration With Global Pharma
10/5/2016 7:11:17 AM BioLineRx Announces Acceptance Of BL-8040 Abstracts For Oral And Poster Presentations At ASH Annual Meeting